Neuroscience

TrkB as a Unifying Target: Rethinking Serotoninergic Antidepressants and Psychedelics

A 2026 review suggests the antidepressant effects of SSRIs and psychedelics may hinge on TrkB signaling, not just serotonin transport, reshaping research and clinical paradigms.

Published November 16, 2026 Read 4 min 809 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Review Highlights TrkB as Central to Antidepressant Mechanisms

A November 2026 peer-reviewed article (OpenAlex W7235359864) asserts that the antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) and serotoninergic psychedelics may be better explained by their action on the tyrosine receptor kinase B (TrkB), rather than solely on the serotonin transporter (SERT). This challenges decades of prevailing pharmacological theory and has immediate implications for research, clinical practice, and regulatory strategy.

SSRIs, such as fluoxetine and sertraline, have long been thought to exert their therapeutic effects primarily by inhibiting SERT, thus increasing synaptic serotonin. However, the review notes that the clinical doses required for efficacy are inconsistent with SERT affinity alone. Instead, recent evidence points to TrkB, a receptor for brain-derived neurotrophic factor (BDNF), as a key molecular target. This mechanism may also underlie the rapid and sustained effects seen with certain psychedelics in clinical trials for depression and obsessive-compulsive disorder (OCD).

Mechanistic Context: Beyond Serotonin Transporter Inhibition

SSRIs and psychedelics may share a final common pathway involving TrkB activation, rather than acting exclusively through serotonin elevation. TrkB is a receptor tyrosine kinase critical for neuroplasticity, synaptic remodeling, and neuronal resilience—factors increasingly recognized as central to depression pathophysiology. The review emphasizes that the pharmacokinetics and pharmacodynamics of SSRIs do not align with SERT as the sole or primary mediator, citing the much lower affinity of SSRIs for TrkB compared to SERT, yet clinical efficacy emerges only at higher, sustained doses.

Psychedelics such as psilocybin and LSD, traditionally classified as serotonin 2A (5-HT2A) receptor agonists, have also demonstrated rapid antidepressant effects in early-phase trials. The review posits that these effects may be mediated, at least in part, by downstream activation of TrkB and BDNF signaling, providing a plausible biological bridge between SSRIs and psychedelics. This insight is not widely covered in mainstream reviews, which often focus on receptor-level pharmacology without integrating neurotrophic mechanisms.

Implications for Drug Development, Trials, and Policy

Recognizing TrkB as a unifying target could reshape how new psychiatric treatments are developed, tested, and regulated. For drug developers, this suggests prioritizing compounds that modulate TrkB or BDNF pathways, either directly or indirectly, and incorporating biomarkers of neuroplasticity into clinical trial endpoints. For clinical trialists, stratifying participants by genetic or molecular markers related to TrkB signaling could improve efficacy signal detection and personalize treatment approaches.

Regulators such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) may need to revisit guidance on mechanism-of-action claims and consider requiring or encouraging neurotrophic biomarker data in new drug applications for antidepressants and psychedelics. This could also influence risk-benefit assessments, particularly if TrkB modulation is linked to specific side effect profiles or long-term neurodevelopmental risks.

Importantly, this mechanistic reframing may inform the debate over the interchangeability or combination of SSRIs and psychedelics in clinical practice, as well as the design of next-generation therapeutics that bypass serotoninergic side effects altogether.

Risks, Unknowns, and Research Gaps

The hypothesis that TrkB is a central mediator of antidepressant effects remains to be fully validated in humans, and several risks and unknowns persist. TrkB is involved in a wide range of neurodevelopmental and neuroplastic processes, raising concerns about potential off-target effects, especially with chronic or high-dose exposure. There is limited data on the long-term safety of TrkB modulation, particularly in vulnerable populations such as adolescents or individuals with neurodegenerative risk factors.

Another challenge is the lack of standardized, clinically validated biomarkers for TrkB activity or BDNF signaling in psychiatric populations. This complicates both drug development and post-market surveillance. Additionally, the review notes that not all patients respond to SSRIs or psychedelics, suggesting that TrkB-related mechanisms may be necessary but not sufficient for therapeutic benefit. Real-world data and head-to-head trials will be needed to clarify these relationships.

A less-discussed failure mode is the risk of overgeneralizing from preclinical or early-phase human data to broad clinical populations. The field must avoid prematurely discarding serotoninergic or other mechanistic models that may still hold relevance for subgroups of patients.

Looking Forward: Integrating Mechanistic Insights into Practice

The identification of TrkB as a potential unifying mechanism for antidepressant effects in SSRIs and psychedelics marks a paradigm shift in psychiatric pharmacology. If validated, this insight could accelerate the development of more targeted, effective, and safer treatments for depression and OCD. It may also prompt regulatory agencies and clinical researchers to update protocols, trial designs, and biomarker strategies to reflect this evolving understanding.

As the field moves forward, interdisciplinary collaboration between molecular neuroscientists, clinical trialists, and regulatory experts will be essential. Ongoing trials and real-world studies should prioritize mechanistic endpoints and long-term safety monitoring to ensure that new treatments deliver on their promise without unforeseen risks.

How we research: This briefing was written and reviewed by Dr. Alex Morgan, PhD (Neuropharmacology), on 2026-11-18. Primary source: OpenAlex W7235359864. Regulatory context was cross-checked against FDA and EMA public guidance as of November 2026.

Primary source: https://openalex.org/W7235359864 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.